Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis

被引:116
作者
Kim, WJ
Yockman, JW
Lee, M
Jeong, JH
Kim, YH
Kim, SW
机构
[1] Univ Utah, Ctr Controlled Chem Delivery, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul 133791, South Korea
关键词
gene therapy; anti-angiogenesis; RGD peptide; soluble Flt-1; VEGF;
D O I
10.1016/j.jconrel.2005.04.016
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Vascular endothelial growth factor (VEGF), a potent angiogenic molecule specific for vascular endothelial cells, is overexpressed in most tumors and closely associated with tumor growth and metastasis. It has been shown that a soluble fragment of VEGF receptor Flt-1 (sFIt-1) has anti-angiogenic properties by way of its antagonist activity against VEGF. In the present study, we demonstrated that the stable expression of sFIt-1 by endothelial cell targeted non-viral gene delivery inhibited the angiogenesis of endothelial cells. A targeted polymeric gene delivery system, PEI-g-PEG-RGD, was developed by incorporating the alpha v beta 3/alpha v beta 5 integrin-binding RGD peptide, ACDCRGDCFC (single-letter amino acid code), into the cationic polymer, polyethylenimine (PEI) via a hydrophilic polyethylene glycol (PEG) spacer. The functional analysis of therapeutic gene encoding sFIt-1/carrier complex was performed with an endothelial cell proliferation assay. The complex of sFlt-1 gene with PEI-g-PEG-RGD conjugate efficiently inhibited the proliferation of cultured endothelial cells, representing that expressed sFIt-1 predominantly bound to exogenous VEGF and blocked the binding of VEGF to the full-length Flt-1 receptor. These findings suggest that the combination of targeted gene carrier and sFlt-1 possesses the potential to be an efficient tool for the anti-angiogenic gene therapy to treat cancer. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 234
页数:11
相关论文
共 38 条
[21]   GLIOBLASTOMA GROWTH INHIBITED IN-VIVO BY A DOMINANT-NEGATIVE FLK-1 MUTANT [J].
MILLAUER, B ;
SHAWVER, LK ;
PLATE, KH ;
RISAU, W ;
ULLRICH, A .
NATURE, 1994, 367 (6463) :576-579
[22]   Angiostatin induces and sustains dormancy of human primary tumors in mice [J].
OReilly, MS ;
Holmgren, L ;
Chen, C ;
Folkman, J .
NATURE MEDICINE, 1996, 2 (06) :689-692
[23]   ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA [J].
OREILLY, MS ;
HOLMGREN, L ;
SHING, Y ;
CHEN, C ;
ROSENTHAL, RA ;
MOSES, M ;
LANE, WS ;
CAO, YH ;
SAGE, EH ;
FOLKMAN, J .
CELL, 1994, 79 (02) :315-328
[24]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285
[25]   alpha v Integrins as receptors for tumor targeting by circulating ligands [J].
Pasqualini, R ;
Koivunen, E ;
Ruoslahti, E .
NATURE BIOTECHNOLOGY, 1997, 15 (06) :542-546
[26]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A POTENTIAL TUMOR ANGIOGENESIS FACTOR IN HUMAN GLIOMAS INVIVO [J].
PLATE, KH ;
BREIER, G ;
WEICH, HA ;
RISAU, W .
NATURE, 1992, 359 (6398) :845-848
[27]   RGD and other recognition sequences for integrins [J].
Ruoslahti, E .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1996, 12 :697-715
[28]   Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle [J].
Schiffelers, RM ;
Ansari, A ;
Xu, J ;
Zhou, Q ;
Tang, QQ ;
Storm, G ;
Molema, G ;
Lu, PY ;
Scaria, PV ;
Woodle, MC .
NUCLEIC ACIDS RESEARCH, 2004, 32 (19) :e149
[29]   An angiogenic, endothelial-cell-targeted polymeric gene carrier [J].
Suh, W ;
Han, SO ;
Yu, L ;
Kim, SW .
MOLECULAR THERAPY, 2002, 6 (05) :664-672
[30]   IDENTIFICATION OF THE KDR TYROSINE KINASE AS A RECEPTOR FOR VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR [J].
TERMAN, BI ;
DOUGHERVERMAZEN, M ;
CARRION, ME ;
DIMITROV, D ;
ARMELLINO, DC ;
GOSPODAROWICZ, D ;
BOHLEN, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 187 (03) :1579-1586